SCAI as a predicted target of miR-495-3p in Breast Cancer

سال انتشار: 1396
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 463

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ICBCMED13_149

تاریخ نمایه سازی: 2 تیر 1397

چکیده مقاله:

Introduction and Aims: breast cancer is a second leading cause of cancer related death in women so understanding the molecular mechanisms underlying this cancer is necessary. Suppressor of cancer invasion (SCAI) is a negative regulator of cancer cells migration and invasion. To best of our knowledge only one study has been done in SCAI targeting by miRNA in breast cancer. The aim of this study is to bioinformatics analysis of SCAI as a target of miR-495-3p in breast cancer.Method: Determination of SCAI, as a potential target of the miR-495-3p was done by using miRNA target prediction algorithms based on miRNA pairing to target sites especially 3’UTR and thermodynamic stability (ΔG) in miRNA target prediction databases including miRDB, DIANA-microT, miRanada, and Target Scan.Result: Target score of SCAI in miRDB was 92. According to miRDB, target score more than 80 indicates that most likely the target is real. MiTG score which ranges from 0 to 1 was 0.9 for miR-495-3p in DIANA microT, so in this database like miRDB, SCAI is a target of miR-495-3p with high probability. mirSVR score in miRanda for miR-495-3p was below -0.1 that is not a suitable score. Also, SCAI was predicted as a target of miR-425-3p in Target Scan (total context score was -0.11), but this score is not very favorable.Conclusion: miRNA dysregulation in breast cancer has crucial impact on tumor development. miR-495-3p has been shown oncogenic role in breast cancer however, its function is still controversial. The results of this study has demonstrated that SCAI could be a novel target of miR-495-3p. Finally, experimental validation of association between SCAI and miR-495-3p is proposed.

نویسندگان

Mohammad Hasan Soheilifar

Research center for molecular medicine and genetics, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran

Abdolvahab Moshtaghian

Deputy of Research and Technology, Semnan University of Medical Sciences, Semnan, Iran

Ali Mahdavinezhad

MD, PhD Research Center for Molecular Medicine, Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran